References

1.
Collins PW, Hirsch S, Baglin TP, Dolan G, Hanley J, Makris M, et al. Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors’ Organisation. Blood 2006;109:1870–7. doi:10.1182/blood-2006-06-029850.
2.
Knoebl P, Marco P, Baudo F, Ccollins P, Huth-Kühne A, Nemes L, et al. Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). Journal of Thrombosis and Haemostasis 2012;10:622–31. doi:10.1111/j.1538-7836.2012.04654.x.
3.
Delgado J, Jimenez-Yuste V, Hernandez-Navarro F, Villar A. Acquired haemophilia: review and meta-analysis focused on therapy and prognostic factors. Br J Haematol 2003;121:21–35. doi:10.1046/j.1365-2141.2003.04162.x.
4.
Borg J, Guillet B, Le Cam-Duchez V, Goudemand J, Lévesque H, SACHA Study Group. Outcome of acquired haemophilia in France: the prospective SACHA (Surveillance des Auto antiCorps au cours de l’Hémophilie Acquise) registry. Haemophilia 2013;19:564–70. doi:10.1111/hae.12138.
5.
Huang S-Y, Tsay W, Lin S-Y, Hsu S-C, Hung M-H, Shen M-C. A study of 65 patients with acquired hemophilia A in Taiwan. J Formos Med Assoc 2015;114:321–7. doi:10.1016/j.jfma.2013.01.006.
6.
Tiede A, Klamroth R, Scharf RE, Trappe RU, Holstein K, Huth-Kühne A, et al. Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01/2010 study. Blood 2015;125:1091–7. doi:10.1182/blood-2014-07-587089.
7.
Franchini M, Capra F, Nicolini N, Veneri D, Manzato F, Baudo F, et al. Drug-induced anti-factor VIII antibodies: a systematic review. Med Sci Monit 2007;13:RA55–61.
8.
Pavlova A, Diaz-Lacava A, Zeitler H, Satoguina J, Niemann B, Krause M, et al. Increased frequency of the CTLA-4 49 A/G polymorphism in patients with acquired haemophilia A compared to healthy controls. Haemophilia 2008;14:355–60. doi:10.1111/j.1365-2516.2007.01618.x.
9.
Oldenburg J, Fosså SD, Ikdahl T. Genetic variants associated with cisplatin-induced ototoxicity. Pharmacogenomics 2008;9:1521–30. doi:10.2217/14622416.9.10.1521.
10.
Tiede A, Eisert R, Czwalinna A, Miesbach W, Scharrer I, Ganser A. Acquired haemophilia caused by non-haemophilic factor VIII gene variants. Ann Hematol 2010;89:607–12. doi:10.1007/s00277-009-0887-3.
11.
Verbruggen B, Novakova I, Wessels H, Boezeman J, Berg M van den, Mauser-Bunschoten E. The Nijmegen modification of the Bethesda assay for factor VIII: C inhibitors: improved specificity and reliability. Thromb Haemost 1995;74:247–51. doi:10.1055/s-0038-1653759.
12.
Baudo F, Collins P, Huth-Kuehne A, Levesque H, Marco P, Nemes L, et al. Management of bleeding in acquired hemophilia A: results from the European Acquired Haemophilia (EACH2) Registry. Blood 2012;120:39–46. doi:10.1182/blood-2012-02-408930.
13.
Astermark J, Donfield SM, DiMichele DM, Gringeri A, Gilbert SA, Waters J, et al. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. Blood 2007;109:546–51. doi:10.1182/blood-2006-04-017988.
14.
Schneiderman J, Rubin E, Nugent D, Young G. Sequential therapy with activated prothrombin complex concentrates and recombinant FVIIa in patients with severe haemophilia and inhibitors: update of our previous experience. Haemophilia 2007;13:244–8. doi:10.1111/j.1365-2516.2007.01451.x.
15.
Sallah S. Treatment of acquired haemophilia with factor eight inhibitor bypassing activity. Haemophilia 2004;10:169–73. doi:10.1046/j.1365-2516.2003.00856.x.
16.
Borg J-Y, Négrier C, Durieu I, Dolimier E, Masquelier A-M, Lévesque H, et al. FEIBA in the treatment of acquired haemophilia a: results from the prospective multicentre French “FEIBA dans l’hemophilie A acquise” (FEIBHAC) registry. Haemophilia 2015;21:330–7. doi:10.1111/hae.12574.
17.
Sumner M, Geldziler B, Pedersen M, Seremetis S. Treatment of acquired haemophilia with recombinant activated FVII: a critical appraisal. Haemophilia 2007;13:451–61. doi:10.1111/j.1365-2516.2007.01474.x.
18.
Varadi K, Negrier C, Berntorp E, Astermark J, Bordet J-C, Morfini M, et al. Monitoring the bioavailability of FEIBA with a thrombin generation assay. J Thromb Haemost 2003;1:2374–80. doi:10.1046/j.1538-7836.2003.00450.x.
19.
Holmström M, Tran H, Holme P. Combined treatment with APCC (FEIBA) and tranexamic acid in patients with haemophilia A with inhibitors and in patients with acquired haemophilia A - a two-centre experience. Haemophilia 2012;18:544–9. doi:10.1111/j.1365-2516.2012.02748.x.
20.
Zanon E, Pasca S, Siragusa S, Napolitano M, Santoro C, Mameli L, et al. Low dose of aPCC after the initial treatment in acquired haemophilia A is useful to reduce bleeding relapses: Data from the FAIR registry. Thromb Res 2019;174:24–6. doi:10.1016/j.thromres.2018.12.006.
21.
Franchini M, Lippi G. Acquired factor VIII inhibitors. Blood 2008;112:250–5. doi:10.1182/blood-2008-03-143586.
22.
Tiede A, Collins P, Knoebl P, Teitel J, Kessler C, Shima M, et al. International recommendations on the diagnosis and treatment of acquired hemophilia A. Haematologica 2020. doi:10.3324/haematol.2019.230771.
23.
Kruse-Jarres R, St-Louis J, Greist A, Shapiro A, Smith H, Chowdary P, et al. Efficacy and safety of OBI-1, an antihaemophilic factor VIII (recombinant), porcine sequence, in subjects with acquired haemophilia A. Haemophilia 2015;21:162–70. doi:10.1111/hae.12627.
24.
Fosbury E, Drebes A, Riddell A, Chowdary P. Review of recombinant anti-haemophilic porcine sequence factor VIII in adults with acquired haemophilia A. Ther Adv Hematol 2017;8:263–72. doi:10.1177/2040620717720861.
25.
Knoebl P, Thaler J, Jilma P, Quehenberger P, Gleixner KV, Sperr WR. Emicizumab for the treatment of acquired hemophilia A. Blood 2020. doi:10.1182/blood.2020006315.
26.
Collins P, Baudo F, Knoebl P, Lévesque H, Nemes L, Pellegrini F, et al. Immunosuppression for acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). Blood 2012;120:47–55. doi:10.1182/blood-2012-02-409185.
27.
Lian EC, Larcada AF, Chiu AY. Combination immunosuppressive therapy after factor VIII infusion for acquired factor VIII inhibitor. Ann Intern Med 1989;110:774–8. doi:10.7326/0003-4819-110-10-774.
28.
Pardos-Gea J, Altisent C, Parra R, Vilardell-Tarres M, Ordi-Ros J. Acquired haemophilia A. First line treatment with calcineurin inhibitors and steroid pulses: a 10-year follow-up study. Haemophilia 2012;18:789–93. doi:10.1111/j.1365-2516.2012.02772.x.
29.
Nemes L. The use of immune tolerance induction regimens for acquired hemophilia. Haemophilia 2004;10:54.
30.
Lian EC-Y, Villar MJ, Noy LI, Ruiz-Dayao Z. Aquired factor VIII inhibitor treated with cyclophosphamide, vincristine, and prednisone. Am J Hematol 2002;69:294–5. doi:10.1002/ajh.10070.
31.
Zeitler H, Ulrich-Merzenich G, Hess L, Konsek E, Unkrig C, Walger P, et al. Treatment of acquired hemophilia by the Bonn-Malmo Protocol: documentation of an in vivo immunomodulating concept. Blood 2005;105:2287–93. doi:10.1182/blood-2004-05-1811.
32.
Goldmann G, Marquardt N, Horneff S, Oldenburg J, Zeitler H. Treatment of minor severe acquired haemophilia. Is there a rationale for immunoadsorption? Atheroscler Suppl 2015;18:74–9. doi:10.1016/j.atherosclerosissup.2015.02.015.
33.
Lindahl R, Nummi V, Lehtinen A, Szanto T, Hiltunen L, Olsson A, et al. Acquired Haemophilia A in four north European countries: survey of 181 patients. British Journal of Haematology 2022;201:326–33. doi:10.1111/bjh.18611.
34.
Srivastava A, Santagostino E, Dougall A, Kitchen S, Sutherland M, Pipe SW, et al. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia 2020;26:1–158. doi:10.1111/hae.14046.
35.
Yu D, Xue F, Liu X, Chen Y, Fu R, Sun T, et al. Acquired hemophilia A: a single-center study of 165 patients. Research and Practice in Thrombosis and Haemostasis 2024;8:102318. doi:10.1016/j.rpth.2024.102318.
36.
Thomas VM, Abou‐Ismail MY, Lim MY. Off‐label use of emicizumab in persons with acquired haemophilia A and von Willebrand disease: A scoping review of the literature. Haemophilia 2021;28:4–17. doi:10.1111/hae.14450.
37.
Shima M, Amano K, Ogawa Y, Yoneyama K, Ozaki R, Kobayashi R, et al. A prospective, multicenter, open-label phase III study of emicizumab prophylaxis in patients with acquired hemophilia A. Journal of Thrombosis and Haemostasis 2023;21:534–45. doi:10.1016/j.jtha.2022.10.004.
38.
Tiede A, Hart C, Knöbl P, Greil R, Oldenburg J, Sachs UJ, et al. Emicizumab prophylaxis in patients with acquired haemophilia A (GTH-AHA-EMI): an open-label, single-arm, multicentre, phase 2 study. The Lancet Haematology 2023;10:e913–21. doi:10.1016/s2352-3026(23)00280-6.
39.
Pfrepper C, Klamroth R, Oldenburg J, Holstein K, Eichler H, Hart C, et al. Emicizumab for the Treatment of Acquired Hemophilia A: Consensus Recommendations from the GTH-AHA Working Group. Hämostaseologie 2023. doi:10.1055/a-2197-9738.
40.
Kempton CL, White GC. How we treat a hemophilia A patient with a factor VIII inhibitor. Blood 2009;113:11–7. doi:10.1182/blood-2008-06-160432.
41.
Schep SJ, Dijk WEM van, Beckers EAM, Meijer K, Coppens M, Eikenboom J, et al. Treatment of acquired hemophilia A, a balancing act: results from a 27‐year Dutch cohort study. American Journal of Hematology 2020;96:51–9. doi:10.1002/ajh.26009.
42.
Wang P, Zhou R, Xue F, Zhou H, Bai J, Wang X, et al. Single‐dose rituximab plus glucocorticoid versus cyclophosphamide plus glucocorticoid in patients with newly diagnosed acquired hemophilia A: A multicenter, open‐label, randomized noninferiority trial. American Journal of Hematology 2023;99:28–37. doi:10.1002/ajh.27128.
43.
Tay L, Duncan E, Singhal D, Al-Qunfoidi R, Coghlan D, Jaksic W, et al. Twelve Years of Experience of Acquired Hemophilia A: Trials and Tribulations in South Australia. Seminars in Thrombosis and Hemostasis 2009;35:769–77. doi:10.1055/s-0029-1245109.
44.
Holstein K, Liu X, Smith A, Knöbl P, Klamroth R, Geisen U, et al. Bleeding and Response to Hemostatic Therapy in Acquired Hemophilia A (AHA): Results from the GTH-AH 01/2010 Study. Blood 2020. doi:10.1182/blood.2019003639.